Literature DB >> 15173195

Preparation of recombinant alpha-thrombin: high-level expression of recombinant human prethrombin-2 and its activation by recombinant ecarin.

Hiroshi Yonemura1, Takayuki Imamura, Kenji Soejima, Yo Nakahara, Wataru Morikawa, Yoshitaka Ushio, Yasuharu Kamachi, Hiroshi Nakatake, Keishin Sugawara, Tomohiro Nakagaki, Chikateru Nozaki.   

Abstract

We have established a large-scale manufacturing system to produce recombinant human alpha-thrombin. In this system, a high yield of alpha-thrombin is prepared from prethrombin-2 activated by recombinant ecarin. We produced human prethrombin-2 using mouse myeloma cells and an expression plasmid carrying the chicken beta-actin promoter and mutant dihydrofolate reductase gene for gene amplification. To increase prethrombin-2 expression further, we performed fed-batch cultivation with the addition of vegetable peptone in 50 liters of suspension culture. After five feedings of vegetable peptone, the expression level of the recombinant prethrombin-2 reached 200 micro g/ml. Subsequently, the recombinant prethrombin-2 could be activated to alpha-thrombin by recombinant ecarin expressed in a similar manner. Finally, recombinant alpha-thrombin was purified to homogeneity by affinity chromatography using a benzamidine-Sepharose gel. The yield from prethrombin-2 in culture medium was approximately 70%. The activity of the purified recombinant alpha-thrombin, including hydrolysis of a chromogenic substrate, release of fibrinopeptide A, and activation of protein C, was indistinguishable from that of plasma-derived alpha-thrombin. Our system is suitable for the large-scale production of recombinant alpha-thrombin, which can be used in place of clinically available alpha-thrombin derived from human or bovine plasma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15173195     DOI: 10.1093/jb/mvh070

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  5 in total

1.  High-level expression and preparation of recombinant human fibrinogen as biopharmaceuticals.

Authors:  Masaki Hirashima; Takayuki Imamura; Kentaro Yano; Ryoichi Kawamura; Akihiro Meta; Yoshiyuki Tokieda; Toshihiro Nakashima
Journal:  J Biochem       Date:  2015-10-15       Impact factor: 3.387

2.  Novel Antibody for the Treatment of Transthyretin Amyloidosis.

Authors:  Akihiko Hosoi; Yu Su; Masaharu Torikai; Hirofumi Jono; Daisuke Ishikawa; Kenji Soejima; Hirofumi Higuchi; Jianying Guo; Mitsuharu Ueda; Genki Suenaga; Hiroaki Motokawa; Tokunori Ikeda; Satoru Senju; Toshihiro Nakashima; Yukio Ando
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

3.  Expression and characterization of recombinant ecarin.

Authors:  Anna Jonebring; Ute Lange; Elke Bucha; Johanna Deinum; Margareta Elg; Ann Lövgren
Journal:  Protein J       Date:  2012-06       Impact factor: 2.371

4.  Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors.

Authors:  Cho Yeow Koh; Sundramurthy Kumar; Maria Kazimirova; Patricia A Nuttall; Uvaraj P Radhakrishnan; Seongcheol Kim; Pudur Jagadeeswaran; Takayuki Imamura; Jun Mizuguchi; Sadaaki Iwanaga; Kunchithapadam Swaminathan; R Manjunatha Kini
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

5.  Recombinant snake venom prothrombin activators.

Authors:  Ann Lövgren
Journal:  Bioengineered       Date:  2012-10-30       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.